The University of Chicago Header Logo

Connection

Mark Talamonti to Receptors, Tumor Necrosis Factor

Back to Details
This is a "connection" page, showing publications Mark Talamonti has written about Receptors, Tumor Necrosis Factor.
Mark Talamonti
Connection Strength
0.021
Receptors, Tumor Necrosis Factor
  1. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.